A prospective trial to evaluate the safety and efficacy of ATI-1501 in children with Clostridium difficile infection

Trial Profile

A prospective trial to evaluate the safety and efficacy of ATI-1501 in children with Clostridium difficile infection

Planning
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Metronidazole (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions
  • Sponsors Appili Therapeutics
  • Most Recent Events

    • 30 Oct 2017 According to an Appili Therapeutics media release, both the US Food and Drug Administration (FDA) and Health Canada have cleared its IND and CTA clinical investigation applications, respectively, to conduct a clinical trial of ATI-1501. The company will begin recruiting subjects in November 2017.
    • 28 Apr 2016 New trial record
    • 12 Apr 2016 According to an Appili Therapeutics media release, the company plans start clinical trials of ATI-1501 for Clostridium difficile infection in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top